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BACKGROUND
High sodium intake increases blood pressure, a risk factor for cardiovascular disease, 
but the effects of sodium intake on global cardiovascular mortality are uncertain.
METHODS
We collected data from surveys on sodium intake as determined by urinary excretion 
and diet in persons from 66 countries (accounting for 74.1% of adults throughout 
the world), and we used these data to quantify the global consumption of sodium 
according to age, sex, and country. The effects of sodium on blood pressure, ac-
cording to age, race, and the presence or absence of hypertension, were calculated 
from data in a new meta-analysis of 107 randomized interventions, and the effects 
of blood pressure on cardiovascular mortality, according to age, were calculated 
from a meta-analysis of cohorts. Cause-specific mortality was derived from the 
Global Burden of Disease Study 2010. Using comparative risk assessment, we es-
timated the cardiovascular effects of current sodium intake, as compared with a 
reference intake of 2.0 g of sodium per day, according to age, sex, and country.
RESULTS
In 2010, the estimated mean level of global sodium consumption was 3.95 g per 
day, and regional mean levels ranged from 2.18 to 5.51 g per day. Globally, 1.65 
million annual deaths from cardiovascular causes (95% uncertainty interval [con-
fidence interval], 1.10 million to 2.22 million) were attributed to sodium intake 
above the reference level; 61.9% of these deaths occurred in men and 38.1% oc-
curred in women. These deaths accounted for nearly 1 of every 10 deaths from 
cardiovascular causes (9.5%). Four of every 5 deaths (84.3%) occurred in low- and 
middle-income countries, and 2 of every 5 deaths (40.4%) were premature (before 
70 years of age). The rate of death from cardiovascular causes associated with 
sodium intake above the reference level was highest in the country of Georgia and 
lowest in Kenya.
CONCLUSIONS
In this modeling study, 1.65 million deaths from cardiovascular causes that oc-
curred in 2010 were attributed to sodium consumption above a reference level of 
2.0 g per day. (Funded by the Bill and Melinda Gates Foundation.)
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Sodium and Death from Cardiovascular Causes
A high dietary intake of sodium is associated with elevated blood pressure, a major risk factor for cardiovascular dis-
ease.1,2 The United Nations,3 World Health Orga-
nization,4 Centers for Disease Control and Pre-
vention, and other organizations have emphasized 
the relationship between dietary sodium and car-
diovascular outcomes.3-7 Yet the global effects of 
sodium consumption and the heterogeneity of 
these effects according to age, sex, and country 
have not been clearly established. Rates of sodi-
um-associated cardiovascular disease have been 
estimated for only selected countries,8-14 and these 
rates are often based on self-reported diet, without 
estimates of salt intake, or without considering 
heterogeneity due to age, race, or the presence or 
absence of hypertension.
As part of the Global Burden of Diseases 
Nutrition and Chronic Diseases Expert Group 
(NUTRICODE), we systematically identified and 
analyzed data on sodium consumption worldwide 
and calculated the dose–response effects of so-
dium on blood pressure in a new meta-analysis of 
trials. We also compiled data to calculate the ef-
fects of blood pressure on cause-specific cardio-
vascular mortality and to characterize current 
blood-pressure levels and numbers of cause-spe-
cific deaths according to country, age, and sex. 
Finally, we used data relating levels of sodium 
intake to blood pressure and cardiovascular events, 
as well as data on the lowest current levels of 
sodium intake according to country, to define a 
reference range for sodium consumption. Using 
all these data (Table S1 in the Supplementary Ap-
pendix, available with the full text of this article 
at NEJM.org), we modeled the estimated impact 
of current levels of sodium intake on cardiovascu-
lar mortality throughout the world.
Me thods
Assessment of Global Sodium Consumption
Between March 2008 and December 2011, we 
performed systematic searches for previously con-
ducted national or subnational surveys on individ-
ual-level sodium consumption based on urinary 
excretion, estimated dietary intake, or both.15,16 
We identified and retrieved data, according to age 
and sex, from published reports or direct con-
tacts for 205 surveys: 142 surveys with data from 
24-hour urine collections and 91 with estimates 
of dietary intake, including 28 with both types 
of data (Table S2 in the Supplementary Appendix). 
These surveys included data from 66 countries, 
accounting for 74.1% of adults in the world. Using 
a hierarchical Bayesian model, we estimated the 
mean level of sodium consumption and statistical 
uncertainty according to age, sex, and calendar 
year in 187 nations. An article with detailed results 
of these analyses has been published previously.16
Our model estimated sodium consumption 
with the use of 24-hour urine collections as the 
reference standard. To make our data comparable 
to data from prior regional surveys and blood-
pressure trials in which urinary sodium levels 
were measured, we did not adjust our analyses 
for sodium loss due to factors other than urinary 
excretion (e.g., sweat).
The funder of this study had no role in its 
design or conduct; in the collection, management, 
analysis, or interpretation of the data; or in the 
preparation, review, approval, or submission of the 
manuscript.
Effects of Reduced Sodium Intake  
on Blood Pressure
Two recent Cochrane meta-analyses evaluated 
randomized trials of the effect of reduced sodi-
um intake on blood pressure.1,2 One meta-analy-
sis was based on the results of 28 trials pub-
lished through 2005.1 The other was based on the 
results of 167 studies and included more recent 
trials, as well as trials involving low reductions 
in sodium intake (<0.46 g [20 mmol] per day) or 
brief interventions (duration of <1 week), which 
were excluded from the first meta-analysis.2 These 
meta-analyses did not determine whether blood-
pressure lowering was linear across a range of 
reduced sodium intakes and did not simultane-
ously quantify heterogeneity according to age, race, 
and the presence or absence of hypertension.
We performed a new meta-analysis evaluating 
all randomized interventions identified in these 
articles1,2 (details are provided in Section S1 in 
the Supplementary Appendix). Using data from 
these trials, we evaluated whether the effects of 
reduced sodium intake on blood pressure were 
linear. We evaluated the potential heterogeneity 
in this effect by taking into account population 
characteristics, including age, the presence or 
absence of hypertension, and race, as well as the 
duration of the intervention. We also assessed 
whether, apart from the presence or absence of 
hypertension, the effects of reduced sodium in-
The New England Journal of Medicine 
Downloaded from nejm.org at UQ Library on August 5, 2018. For personal use only. No other uses without permission. 
 Copyright © 2014 Massachusetts Medical Society. All rights reserved. 
n engl j med 371;7 nejm.org August 14, 2014626
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
take on blood-pressure lowering were blunted by 
the use of antihypertensive medication.
Effects of Blood-Pressure Levels on 
Cardiovascular Mortality
To calculate the effects of systolic blood pressure 
on deaths from cardiovascular causes, we com-
bined results from two large international projects 
(totaling 99 cohorts, 1.38 million participants, 
and 65,000 cardiovascular events) that pooled 
individual-level data, consistently adjusted for 
confounding. We accounted for regression dilu-
tion bias based on serial blood-pressure mea-
sures over time.17,18 We interpolated and extrapo-
lated age-specific proportional effects (relative 
risks) of systolic blood pressure on cardiovascu-
lar mortality in 10-year age groups across the 
pooling projects (see Section S2 and Fig. S3 in 
the Supplementary Appendix).19 We used the 
same estimates of relative risk according to sex 
and race, on the basis of evidence of generally 
similar proportional effects of blood pressure on 
cardiovascular events according to sex and race 
in trials of antihypertensive drugs and observa-
tional studies of blood pressure and cardiovas-
cular events.19
Reference Levels of Sodium Consumption
To define reference levels of sodium consump-
tion, we conducted a search of published survey 
data, cohort studies, controlled trials, and dietary 
recommendations, as previously reported.15 We 
determined levels of sodium consumption that 
were associated with the lowest blood-pressure 
levels in ecologic studies and in randomized tri-
als and with the lowest risk of disease in meta-
analyses of prospective cohort studies. We also 
considered at least theoretical feasibility based 
on the lowest national mean levels of consump-
tion globally. Finally, we considered the consisten-
cy of our identified reference intake levels with 
major dietary guidelines. Details are provided in 
Section S4 in the Supplementary Appendix.
Current Blood-Pressure Levels and Cause-
Specific Mortality
Data on current blood-pressure levels and cardio-
vascular mortality, each according to country, age, 
and sex, were compiled as part of the Global 
Burden of Disease Study 2010.20,21 Data on blood 
pressure (from 786 country-years and 5.4 million 
participants) were obtained from published and 
unpublished health examination surveys and epi-
demiologic studies from around the world. Data 
on causes of death were obtained for 187 countries 
from 1980 through 2010; these data were obtained 
from vital-registration systems, verbal autopsies, 
mortality surveillance, census data, surveys, hos-
pitals, police records, and mortuaries. Details of 
data collection and the statistical modeling used to 
estimate mean systolic blood pressure and cause-
specific mortality are provided in Table S1 and Sec-
tions S5 and S6 in the Supplementary Appendix.
Cardiovascular Mortality Associated with 
Sodium Consumption above the Reference Level
We estimated disease burdens using comparative 
risk assessment,22 capturing geographic and demo-
graphic variations in sodium intake, blood pres-
sure, cardiovascular mortality, and corresponding 
uncertainties (details are provided in Table S1 and 
Section S7 in the Supplementary Appendix). We 
incorporated age-specific and sex-specific sodi-
um intake, blood-pressure level, relative risk, 
and mortality data for each country to model the 
fraction and numbers of deaths estimated to be 
attributable to sodium intake above the refer-
ence level.
The population-attributable fraction was esti-
mated in a two-step process. First, we used the 
effects of sodium consumption on blood pressure 
according to age, the presence or absence of hy-
pertension, and race to calculate the change in 
mean systolic blood pressure that would be ex-
pected from reducing sodium consumption to 
reference levels as defined above. Second, we 
used the age-specific effects of blood pressure on 
cardiovascular mortality to calculate the resulting 
change in risk. Estimated numbers of deaths at-
tributable to sodium intake above the reference 
level were calculated by multiplying the popula-
tion-attributable fraction by the absolute number 
of deaths in each country, age, and sex stratum.
Statistical Analysis
Analyses were performed with the use of R statis-
tical software, version 2.15.0.
R esult s
Global Sodium Consumption
We estimated that in 2010, the mean level of con-
sumption of sodium worldwide was 3.95 g per day, 
and regional means ranged from 2.18 to 5.51 g 
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per day (Fig. S1 in the Supplementary Appen-
dix).16 Overall, 181 of 187 countries — 99.2% of 
the adult population in the world — had esti-
mated mean levels of sodium intake exceeding 
the World Health Organization recommendation 
of 2.0 g per day, and 119 countries — 88.3% of 
the adult population in the world — exceeded this 
recommended level by more than 1.0 g per day.
Effects of Reduced Sodium Intake on Blood 
Pressure
In our primary analysis of reduced sodium intake 
and blood pressure, we found strong evidence of 
a linear dose–response relationship (P < 0.001 for 
linearity and P = 0.58 for nonlinearity) (Fig. 1A). 
When the data were evaluated with the use of 
inverse-variance weighted meta-regression, each 
reduction of 2.30 g of sodium per day was associ-
ated with a reduction of 3.82 mm Hg (95% con-
fidence interval [CI], 3.08 to 4.55) in blood pres-
sure (Fig. 1B).
The effects of dietary sodium on blood pres-
sure were modified according to population char-
acteristics, with larger reductions in blood pres-
sure among older persons than among younger 
persons (Fig. S2 in the Supplementary Appendix), 
among blacks than among whites, and among 
hypertensive persons than among normotensive 
persons. For a white, normotensive population at 
50 years of age, each reduction of 2.30 g per day 
in sodium intake lowered systolic blood pressure 
by 3.74 mm Hg (95% CI, 2.29 to 5.18). We did 
not find evidence of substantial blunting of the 
blood-pressure–lowering effects of sodium restric-
tion by antihypertensive drugs, although the data 
available to address this question were limited. 
Further details are provided in Section S1 in the 
Supplementary Appendix.
Effects of Blood Pressure on Cardiovascular 
Mortality
The pooled analyses of blood pressure and car-
diovascular mortality showed a log-linear (pro-
portional) dose–response relationship, with no 
evidence of a threshold as low as a systolic blood 
pressure of at least 115 mm Hg (see Section S2 
and Fig. S3 in the Supplementary Appendix).19 The 
relative magnitude of the effect on blood pressure 
decreased with age, in a manner similar to that 
seen with other cardiovascular risk factors.19
Figure 1. Effects of Reduced Sodium Intake on Systolic Blood Pressure.
Data are from 103 trials and include 107 comparison interventions  
(6970 persons). Reductions in sodium intake ranged from 0.53 to 6.56 g 
(23 to 285 mmol) per day (mean±SD, 2.28±1.27), the duration of the inter-
vention ranged from 7 to 1100 days (mean±SD, 65±160 ), and the age of 
the participants ranged from 13 to 73 years (mean±SD, 47.4±14.4). As 
shown in Panel A, the effect of reduced sodium intake on systolic blood 
pressure was linear (P < 0.001 for linearity), and there was little evidence of 
nonlinearity (P = 0.58 for nonlinearity). The solid line represents the central 
estimate, and the dotted lines the 95% confidence intervals [CIs]. The 
model is based on inverse-variance–weighted, restricted-cubic-spline re-
gression adjusted for age, race, and the presence or absence of hyperten-
sion. As shown in Panel B, this relationship was further examined with the 
use of inverse-variance–weighted linear meta-regression. Each circle repre-
sents one randomized comparison of the intervention with the control 
group in each trial, and the size of the circle corresponds to its inverse-
variance weight. The fitted line represents the effect of reduced sodium  
intake across all trials (i.e., the effect according to the meta-analysis).  
Each reduction in sodium intake of 2.30 g (100 mmol) per day was associ-
ated with a reduction of 3.82 mm Hg (95% CI, 3.08 to 4.55) in systolic 
blood pressure.
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Reference Levels of Sodium Consumption
Potential reference levels of sodium consumption 
according to various definitions are shown in 
Table S3 in the Supplementary Appendix. The 
lowest mean intake associated with both lower 
systolic blood pressure and a lower positive rela-
tionship between higher age and blood pressure 
in ecologic studies was 614 mg of sodium per 
day.23 In large, well-controlled, randomized feed-
ing trials, the lowest tested sodium intake for 
which reductions in blood-pressure levels were 
clearly documented was 1500 mg per day.24 In 
prospective observational studies, the lowest mean 
sodium intake associated with a lower risk of car-
diovascular events ranged from 1787 to 2391 mg 
per day.25 We also considered observed mean lev-
els of sodium intake that have been associated 
with the lowest risk of stomach cancer (1245 mg 
per day).26 Levels of sodium intake associated with 
the lowest risk ranged from 614 to 2391 mg per 
day, depending on the type of evidence and the 
outcome. According to national data on sodium 
consumption,16 the estimated lowest observed 
mean national intake level was approximately 
1500 mg per day. The maximum level of sodium 
intake recommended in major dietary guidelines 
ranged from 1200 to 2400 mg per day.4,7,27-30
To estimate cardiovascular mortality attribut-
able to sodium consumption, we used a reference 
level corresponding to a population mean (±SD) 
intake of 2.0±0.2 g of sodium per day. In sensitiv-
ity analyses, we evaluated a lower reference intake 
level, 1.0±0.1 g per day. We also estimated cardio-
vascular mortality attributable to sodium consump-
tion above a reference intake level of 4.0±0.4 g 
per day, which is approximately the current mean 
global intake level.
Estimated Cardiovascular Mortality 
Attributed to Sodium Consumption
On the basis of the correlations between sodium 
intake and blood pressure and between blood 
pressure and cardiovascular mortality that are 
described above, and using a reference level of so-
dium intake of 2.0±0.2 g per day, we found that 
1.65 million deaths from cardiovascular causes 
(95% uncertainty interval, 1.10 million to 2.22 mil-
lion) worldwide in 2010 were attributable to sodi-
um consumption above the reference level (Ta-
ble 1, and Table S4 in the Supplementary 
Appendix). Of these deaths, 687,000 (41.7%) 
were due to coronary heart disease, 685,000 
(41.6%) were due to stroke, and 276,000 (16.7%) 
were due to other cardiovascular disease. Glob-
ally, 40.4% of these deaths occurred prematurely 
(i.e., in persons younger than 70 years of age) 
(see Section S8 and Fig. S4 in the Supplementary 
Appendix). Four of every 5 sodium-associated 
deaths from cardiovascular causes (84.3%) oc-
curred in low-income and middle-income coun-
tries. In sum, approximately 1 of every 10 deaths 
from cardiovascular causes worldwide (9.5%) 
(95% uncertainty interval, 6.4 to 12.8) and 
nearly 1 of every 5 (17.8%) premature deaths 
from cardiovascular causes were attributed to 
sodium consumption above the reference level.
Across nine regions of the world, the absolute 
rate of sodium-associated deaths from cardio-
vascular causes was highest in Central Asia and 
Eastern and Central Europe (Fig. 2A, and Fig. S5 
and Table S4 in the Supplementary Appendix). 
Proportional cardiovascular mortality was high 
in all regions: among younger adults, it exceeded 
10% in nearly all regions and it exceeded 20% in 
Central Asia and Eastern and Central Europe, 
East Asia, and Southeast Asia (Fig. 2B). Among 
older adults, who have a higher absolute risk and 
more competing risk factors, proportional sodi-
um-associated cardiovascular mortality ap-
proached or exceeded 10% in Central Asia and 
Eastern and Central Europe, East Asia, and 
Southeast Asia. Most sodium-associated cardio-
vascular deaths were due to coronary heart dis-
ease, except in East Asia, Southeast Asia, and 
sub-Saharan Africa, where most deaths from 
cardiovascular causes were due to stroke, espe-
cially hemorrhagic and other nonischemic 
strokes (Table S4 and Fig. S5 in the Supplemen-
tary Appendix).
Across individual nations, substantial varia-
tion was evident. Sodium-associated cardiovas-
cular mortality was highest in the country of 
Georgia (1967 deaths per 1 million adults per 
year; 95% uncertainty interval, 1321 to 2647) 
and lowest in Kenya (4 deaths per 1 million 
adults per year; 95% uncertainty interval, 3 to 6) 
(Fig. 3). Proportional cardiovascular mortality 
ranged from 27.4% in Mauritius (95% uncer-
tainty interval, 18.8 to 35.9) to 0.3% in Kenya 
(95% uncertainty interval, 0.2 to 0.4) (Fig. 4). 
Among the 30 most populous nations (Fig. S6 in 
the Supplementary Appendix), the highest sodi-
um-associated cardiovascular mortality was in 
Ukraine (1540 deaths per 1 million adults per 
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year; 95% uncertainty interval, 1017 to 2099), 
and the highest proportional mortality was in 
China (15.3% of all cardiovascular deaths; 95% 
uncertainty interval, 10.5 to 20.2). Detailed in-
formation about individual nations is provided 
in Section S9 and Table S5 in the Supplementary 
Appendix.
 In sensitivity analyses, lowering the definition 
of the reference intake level from 2.0 to 1.0 g of 
sodium per day increased the number of deaths 
from cardiovascular causes in the world that 
were attributed to sodium consumption by ap-
proximately 40%, to 2.30 million (95% uncertainty 
interval, 1.55 million to 3.07 million) (Tables S6 
Figure 2. Cardiovascular Mortality Attributed to Sodium Consumption of More than 2.0 g per Day in 2010, According to Age and Region.
 For a complete listing of countries included in each region, see Table S4 in the Supplementary Appendix. Panel A shows the absolute 
cardiovascular mortality (number of deaths per 1 million adults per year) attributed to sodium consumption above 2.0 g per day. Panel 
B shows the proportional cardiovascular mortality (the percentage of all deaths from cardiovascular causes) attributed to sodium con-
sumption above 2.0 g per day. Vertical lines represent 95% uncertainty (confidence) intervals.
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and S7 and Fig. S7 and S8 in the Supplementary 
Appendix). When we estimated effects attribut-
able only to sodium intake above 4.0±0.4 g per 
day, 512,901 worldwide deaths from cardiovascu-
lar causes (95% uncertainty interval, 333,710 to 
704,773) were attributed to such consumption 
(Tables S8 and S9 in the Supplementary Appen-
dix). This was the estimated number of deaths 
that were potentially preventable if only the na-
tions with the highest level of sodium consump-
tion lowered their intake to just the current mean 
intake in the world. If we altered our model so that 
the estimated benefits of blood-pressure lowering 
did not continue below 125 mm Hg, 1.55 million 
deaths from cardiovascular causes in the world 
(95% uncertainty interval, 1.10 million to 2.10 
million) were attributed to sodium consumption 
above a level of 2.0 g per day.
Discussion
We used currently available data on sodium con-
sumption, dose–response effects on blood pres-
sure and on cardiovascular mortality, and cause-
specific deaths to estimate the effect of current 
sodium intake on cardiovascular mortality world-
wide. Globally, 1.65 million deaths from cardio-
vascular causes in 2010 — about 1 of 10 deaths 
from cardiovascular causes — were attributed to 
sodium consumption of more than 2.0 g per day. 
Notably, 4 of 5 of these deaths occurred in low- 
and middle-income countries, and 2 of 5 of these 
deaths occurred prematurely (before the age of 
70 years).
Our findings also show and quantify the het-
erogeneity in disease burden attributed to sodium 
according to region, age, and type of cardiovascu-
lar disease. Yet, we also found that no region and 
few countries were spared. Whereas estimated 
sodium-associated cardiovascular mortality was 
highest in Central Asia, it was high (more than 
750 deaths per 1 million adults who were 70 years 
of age or older) in all regions. The estimated 
number of proportional sodium-associated deaths 
was also high, approaching or exceeding 15% of 
premature deaths from cardiovascular causes in 
most regions.
Our meta-analysis of 107 randomized interven-
tions in 103 trials showed a linear dose–response 
relationship between reduced sodium intake and 
blood pressure, jointly modified according to age, 
race, and the presence or absence of hypertension. 
These findings are consistent with the findings 
of a meta-analysis, published after submission 
Figure 3. Absolute Cardiovascular Mortality Attributed to Sodium Consumption of More than 2.0 g per Day in 2010, According to Nation.
The scale is based on the number of deaths from cardiovascular causes (per 1 million persons) in 2010 that were attributed to sodium 
consumption of more than 2.0 g per day.
25 50 300 500 900 20000
Deaths per 1 Million Population
The New England Journal of Medicine 
Downloaded from nejm.org at UQ Library on August 5, 2018. For personal use only. No other uses without permission. 
 Copyright © 2014 Massachusetts Medical Society. All rights reserved. 
n engl j med 371;7 nejm.org August 14, 2014632
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
of this article, that included fewer trials (34 tri-
als).31 Larger effects in older adults and hyper-
tensive persons would be consistent with de-
creasing vascular compliance and renal filtration; 
in blacks, larger effects would be consistent with 
differences in renal handling of sodium.32-34 We 
used randomized trials of reduced sodium in-
take and blood pressure to estimate the more 
conceptually appropriate effect of lifetime differ-
ences in intake, because direct evidence on lifetime 
effects, which may be larger, is available only from 
ecologic comparisons and experiments involving 
nonhuman primates.35
Some researchers have argued that it may not 
be possible to directly extrapolate the effects of 
sodium on blood pressure to cardiovascular risk. 
However, the effect on cardiovascular disease is 
supported by extensive experimental and ecologic 
evidence, data on cardiovascular events from some 
trials of reduced sodium intake, and evidence of 
the cardiovascular benefits of blood-pressure 
lowering across multiple interventions (see Sec-
tion S3 in the Supplementary Appendix).5,7,36,37 A 
meta-analysis of prospective cohort studies showed 
that higher sodium consumption was associated 
with a higher rate of death from coronary heart 
disease (relative risk, 1.32; 95% CI, 1.13 to 1.53) 
and death from stroke (relative risk, 1.63; 95% 
CI, 1.27 to 2.10), the two main end points in our 
analysis.25 Although concerns have been raised 
that reduced sodium intake may cause physiologi-
cal harm, a meta-analysis of 37 trials showed no 
significant adverse effects on blood lipid levels, 
catecholamine levels, or renal function.25
There is mixed evidence from observational 
data on the relationship between very low sodium 
intake and cardiovascular events. A recent Insti-
tute of Medicine report concluded that, if restricted 
to studies of clinical cardiovascular events, there 
is insufficient evidence that lowering sodium 
intake further beyond 2.30 g per day either in-
creases or decreases the occurrence of cardiovas-
cular disease.38 Yet the report further concluded 
that the entirety of the evidence, “when consid-
ered collectively, indicates a positive relationship 
between higher levels of sodium intake and [the] 
risk of cardiovascular disease.”38 Although pre-
cise targets for sodium reduction remain contro-
versial, various organizations tasked with review-
ing all the evidence have arrived at target levels 
ranging from 1200 to 2400 mg per day (Table S3 
in the Supplementary Appendix).
Figure 4. Proportion of Deaths from Cardiovascular Disease Attributed to Sodium Consumption of More than 2.0 g per Day in 2010,  
According to Nation.
The scale is based on the percentage of all deaths from cardiovascular causes in 2010 that were attributed to sodium consumption of 
more than 2.0 g per day.
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The potential limitations of our study should 
be considered. Although we made every effort to 
maximize validity, minimize error and bias, and 
incorporate heterogeneity and uncertainty, our 
modeling cannot prove that sodium restriction 
reduces cardiovascular mortality. Our primary 
metric for estimating dietary sodium was based 
on 24-hour urine collections, which reflect ap-
proximately 90% of intake and also can be lim-
ited by incomplete collection. Data on sodium 
intake were not available across all countries or 
years; this increased statistical uncertainty and 
the risk that some data could reflect sampling 
bias. We focused on cardiovascular mortality, 
but dietary sodium is also associated with non-
fatal cardiovascular disease, kidney disease, and 
gastric cancer,26 the second-leading fatal cancer 
worldwide.21 Consequently, our findings may un-
derestimate the full global health effects of di-
etary sodium. We did not have data on potassium 
consumption, which also influences blood pres-
sure and the risk of stroke.39,40 Our model did 
not incorporate specific approaches or timelines 
for reduced sodium intake, which could be in-
formed by other efforts.41-43
In conclusion, we carried out a study to model 
the estimated effect of sodium consumption on 
cardiovascular mortality. On the basis of currently 
available data on sodium consumption, dose–
response effects on blood pressure and cardio-
vascular mortality, and cause-specific deaths, 
we estimate that in 2010, a total of 1.65 million 
deaths from cardiovascular causes were attribut-
able to consumption of more than 2.0 g of sodium 
per day.
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